Exploration of Targeted Anti-tumor Therapy

Table 4

Comparison of clinico-pathological features between patients with good and poor mALI

Parameter		Total	Pre-chemotherapy mALI		Total	Post-chemotherapy mALI		P-value (sex)
Parameter		Total	Good (> 55.33)	Poor (≤ 55.33)	Total	Good (> 55.33)	Poor (≤ 55.33)	Baseline	Post-chemotherapy
BMI	< 18.5%	285	17	39	-	-	-	0.17	-
	18.5–24.99%		65	96
	25.0–29.99%		25	36
	≥ 30%		5	2
Smoker	Yes	285	26	33	274	30	24	0.40	0.75
Smoker	No	285	86	140	274	117	103	0.40	0.75
Age	≤ 65 Years	285	96	156	274	136	109	0.25	0.07
Age	> 65 Years	285	16	17	274	11	18	0.25	0.07
SMD	Good (> 36.62)	285	47	53	274	63	38	0.05	0.03
SMD	Poor (≤ 36.62)	285	65	120	274	84	89	0.05	0.03
Gender	Male	285	67	92	274	88	62	0.27	0.07
Gender	Female	285	45	81	274	59	65	0.27	0.07
ALI	Good (> 28.02)	285	95	13	-	-	-	0	-
ALI	Poor (≤ 28.02)	285	17	160	-	-	-	0	-
Sarcopenia	Yes	285	54	108	274	80	92	0.02	0
Sarcopenia	No	285	58	65	274	67	35	0.02	0
NLR	Good (≤ 3)	285	95	15	274	137	14	0	0
NLR	Poor (> 3)	285	17	158	274	10	113	0	0
Chemotherapy regimen received	Geftinib	285	49	94	-	-	-	0.08	-
Chemotherapy regimen received	Pemetrexed plus platins	285	63	79	-	-	-	0.08	-
Grades of drug toxicity	High grade	273	66	104	-	-	-	0.74	-
Grades of drug toxicity	Low grade	273	39	64	-	-	-	0.74	-
Performance status	0–1	285	104	164	274	138	120	0.50	0.83
Performance status	≥ 2	285	8	9	274	9	7	0.50	0.83
Progression	Yes	285	84	126	-	-	-	0.68	-
Progression	No	285	28	47	-	-	-	0.68	-
Final status	Alive	285	33	34	-	-	-	0.06	-
Final status	Dead	285	79	139	-	-	-	0.06	-

-: not applicable. Bold values indicate significant P-values